Department of Medical Biotechnologies, University of Siena, Santa Maria alle Scotte University Hospital, Viale Bracci, 53100 Siena, Italy.
Department of Experimental and Clinical Medicine, University of Florence, Careggi University Hospital, Largo Brambilla, Florence, Italy.
J Antimicrob Chemother. 2022 Jul 28;77(8):2199-2208. doi: 10.1093/jac/dkac142.
To investigate the in vitro activity of fosfomycin, colistin and combinations thereof against planktonic and biofilm cultures of Gram-negative pathogens, mostly showing MDR phenotypes, at concentrations achievable via inhalation of aerosolized drugs.
Activity against planktonic cultures was tested by the chequerboard assay with 130 strains, including 52 Pseudomonas aeruginosa, 47 Klebsiella pneumoniae, 19 Escherichia coli, 7 Stenotrophomonas maltophilia and 5 Acinetobacter baumannii. Activity against biofilm cultures was tested by biofilm chequerboard and quantitative antibiofilm assays with a subset of 20 strains. In addition, 10 of these strains were tested in mutant prevention concentration (MPC) assays.
Against planktonic cultures, synergism between fosfomycin and colistin was detected with a minority (10%) of strains (eight K. pneumoniae and five P. aeruginosa), while antagonism was never observed. Synergism between fosfomycin and colistin against biofilms was observed with the majority of tested strains (16/20 in biofilm chequerboard assays, and 18/20 in the quantitative antibiofilm assays), including representatives of each species and regardless of their resistance genotype or phenotype. Furthermore, combination of fosfomycin and colistin was found to significantly reduce the MPC of individual drugs.
Fosfomycin and colistin in combination, at concentrations achievable via inhalation of nebulized drugs, showed notable synergy against MDR Gram-negative pathogens grown in biofilm, and were able to reduce the emergence of fosfomycin- and colistin-resistant subpopulations.
研究在可通过吸入雾化药物达到的浓度下,磷霉素、黏菌素及其组合对浮游和生物膜培养的革兰氏阴性病原体(主要表现为多药耐药表型)的体外活性。
通过棋盘微量稀释法对 130 株菌株(包括 52 株铜绿假单胞菌、47 株肺炎克雷伯菌、19 株大肠埃希菌、7 株嗜麦芽窄食单胞菌和 5 株鲍曼不动杆菌)进行浮游培养物活性检测。通过生物膜棋盘微量稀释法和定量抗生物膜试验对 20 株菌株的亚组进行生物膜培养物活性检测。此外,对其中的 10 株菌株进行突变预防浓度(MPC)检测。
对浮游培养物,在少数(10%)菌株(8 株肺炎克雷伯菌和 5 株铜绿假单胞菌)中检测到磷霉素和黏菌素之间存在协同作用,而从未观察到拮抗作用。在大多数测试菌株(生物膜棋盘微量稀释试验中为 16/20,定量抗生物膜试验中为 18/20)中观察到磷霉素和黏菌素对生物膜的协同作用,包括每个物种的代表,且无论其耐药基因型或表型如何。此外,发现磷霉素和黏菌素联合使用可显著降低单独药物的 MPC。
在可通过吸入雾化药物达到的浓度下,磷霉素和黏菌素联合使用,对生物膜中生长的多药耐药革兰氏阴性病原体表现出显著的协同作用,并能够减少磷霉素和黏菌素耐药亚群的出现。